Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (Nasdaq: AXGT) (“Axovant”) today announced […]